Endra Life Sciences Inc Stock Price, News & Analysis

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced its financial results for Q4 and full year 2022, reporting a net loss of $3.3 million for Q4 2022, compared to a loss of $3.1 million in Q4 2021. For the entire year, the company recorded a net loss of $13.2 million, up from $11.2 million in 2021. Operating expenses increased to $3.3 million in Q4 2022 and $13.2 million for the year, primarily due to ongoing product development and commercialization efforts. ENDRA is pursuing FDA approval for its TAEUS liver device, having performed over 100 scans in 2022. The company has also extended its collaboration with GE HealthCare through December 2024.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced its upcoming financial results for the year ending December 31, 2022, set to be released on March 14, 2023, after U.S. market close. A conference call and webcast will commence at 4:30 p.m. Eastern time to discuss the results and provide updates on corporate developments. Participants can pre-register and access the call through provided links or by dialing specific numbers for U.S. and international callers. ENDRA is known for its innovative Thermo Acoustic Enhanced Ultrasound (TAEUS®) technology aimed at improving diagnostic tools for chronic liver diseases affecting over one billion patients globally.

ENDRA Life Sciences (NASDAQ: NDRA) announced a 1-for-20 reverse stock split to comply with Nasdaq's minimum bid price requirement, reducing outstanding shares from approximately 63 million to 3.16 million. The split follows stockholder approval on November 29, 2022. Chairman Francois Michelon expressed gratitude to stockholders and emphasized that the higher share price may attract institutional investors. The stock will begin trading on a split-adjusted basis shortly, and details are in the definitive proxy statement filed on October 17, 2022.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) reported its financial results for Q3 2022, highlighting significant progress in clinical evaluations for its TAEUS liver device, with 95 scans performed year-to-date. The company is finalizing its De Novo FDA submission documentation aimed at assessing Non-Alcoholic Fatty Liver Disease (NAFLD). Operating expenses rose to $3.4 million, with a net loss of $3.4 million, or $0.05 per share. ENDRA maintains a strong cash position of $8 million to support ongoing commercialization efforts.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report its third-quarter financial results on November 14, 2022, after market close. A conference call is scheduled for 4:30 p.m. Eastern time to discuss the results and provide updates on corporate developments. ENDRA's innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology aims to visualize tissues at a fraction of MRI costs. This technology specifically targets liver conditions affecting over one billion people worldwide, with potential applications in various clinical areas.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents from the U.S. Patent and Trademark Office, bringing its total to 33 patents in the U.S. These patents include U.S. Patent No. 11456518, which covers manufacturing methods for a radio frequency applicator, and U.S. Patent No. 11478153, focusing on monitoring tissue temperature during surgical procedures. The company aims to enhance its thermoacoustic imaging systems and expand applications for its TAEUS technology, particularly in assessing liver health and temperature visualization during surgeries.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present a company overview at the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, in a virtual format, alongside one-on-one meetings. ENDRA has developed the Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, a cost-effective imaging solution aimed at diagnosing liver conditions affecting over one billion people globally. TAEUS® is designed to work with existing ultrasound systems and focuses on non-invasive liver fat measurement, relevant for Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced significant progress in preparing a De Novo request for its Thermo Acoustic Enhanced UltraSound (TAEUS) system to the U.S. FDA. Completion of documentation is expected by the end of Q3, with the submission anticipated shortly thereafter. The TAEUS system, designed to non-invasively assess Non-Alcoholic Fatty Liver Disease (NAFLD), is already CE-marked for sale in Europe. A successful De Novo request could enhance its market position in the U.S., targeting over one billion people affected by NAFLD globally.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York City. A webcast will be available on-demand starting September 12, 2022, at 7:00 a.m. Eastern Time. The company will also participate in key clinical industry conferences in Dublin, Leeds, Dijon, and Washington D.C. to showcase its Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at assessing liver conditions affecting over one billion people globally.